Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bitdeer Technologies Group — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Bitdeer Technologies Group trades at $12.15 (market cap $3.13B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| ACAD | BTDR | |
|---|---|---|
Market Cap | $4.49B | $3.13B |
Sector | Health | Technology |
52-Week High | $28.06 | $25.90 |
52-Week Low | $20.06 | $7.28 |
Enterprise Value | $3.69B | $4.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BTDR trades at $14.25, up 2.89% today, with a bullish technical signal despite recent earnings misses. The company reported Q1 2026 revenue growth of 170% year-over-year to $188.9 million but posted a net loss. Analyst consensus is strongly bullish with an 81.82% buy rating and a $23.40 price target, suggesting significant upside. Recent developments include expansion into AI cloud infrastructure and new data center agreements in Norway and Canada.
The outlook for BTDR is mixed, with strong revenue growth and strategic AI expansion offset by persistent net losses and negative profit margins. Key risks include execution challenges in new ventures and sensitivity to Bitcoin market volatility. The stock presents a high-risk, high-reward opportunity, supported by Wall Street optimism but requiring careful monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
